Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/89300
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Resistance to anti-HCV protease inhibitors |
Author: | Thompson, A.J. Locarnini, S.A. Beard, M.R. |
Citation: | Current Opinion in Virology, 2011; 1(6):599-606 |
Publisher: | Elsevier |
Issue Date: | 2011 |
ISSN: | 1879-6257 1879-6265 |
Statement of Responsibility: | Alexander J Thompson, Stephen A Locarnini, and Michael R Beard |
Abstract: | The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges. For the first time, drug resistance has become an issue to consider in the management of HCV. This brief review summarizes the current literature concerning resistance to the HCV NS3 protease inhibitors, both experimental and clinical, and identifies the key questions facing the field. |
Keywords: | Humans Hepacivirus Hepatitis C, Chronic Proline Oligopeptides Viral Nonstructural Proteins Protease Inhibitors Drug Resistance, Viral Virus Replication Models, Molecular |
Rights: | © 2011 Elsevier B.V. All rights reserved. |
DOI: | 10.1016/j.coviro.2011.10.001 |
Published version: | http://dx.doi.org/10.1016/j.coviro.2011.10.001 |
Appears in Collections: | Aurora harvest 7 Microbiology and Immunology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.